Compare Albertsons Companies Inc (ACI) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Albertsons Companies Inc vs Sanofi SA — how do they compare? Albertsons Companies Inc trades at $11.99 (market cap $5.95B), while Sanofi SA trades at $43.71 (market cap $104.30B). The key difference: Sanofi SA is far larger — about 17.5× Albertsons Companies Inc's market cap, and Sanofi SA is trading nearer its 52-week high, Albertsons Companies Inc nearer its low. Which is the better fit depends on your goals.
| ACI | SNY | |
|---|---|---|
Market Cap | $5.95B | $104.30B |
Sector | Consumer Staples | Health |
52-Week High | $19.74 | $52.34 |
52-Week Low | $11.03 | $41.33 |
Enterprise Value | $21.35B | $124.19B |
Dividend Yield | 5.55% | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Albertsons (ACI) trades at $11.98, down 1.24% with bearish technical signals despite recent insider buying by the CEO and CFO. The stock shows mixed fundamentals with strong revenue growth to $80.39B in 2025 but declining net margins to 0.08%. Recent Q2 2026 earnings missed expectations, triggering a 22% selloff and multiple legal investigations. Analyst consensus remains cautious with a $13.20 price target and 56.52% hold rating.
ACI presents a high-risk opportunity trading near multi-year lows with potential upside to analyst targets. Key catalysts include ACI Edge restructuring and digital initiatives, but investors face significant execution risks amid margin pressure and competitive grocery markets. The stock's deep value case is complicated by earnings volatility and ongoing legal scrutiny.
SNY trades at $43.62, up 0.32% today, with a neutral technical signal and bullish moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 outlook. Revenue for 2025 was $46.72B with net income of $7.81B, showing improved profitability. Analyst consensus is mixed with 44% Buy, 52% Hold, and 4% Sell ratings. Recent news highlights regulatory approvals for new drugs and pipeline developments under new CEO leadership.
The outlook for SNY is cautiously optimistic, driven by Dupixent's growth and new drug approvals, but faces risks from pipeline setbacks and competition. Earnings momentum and cost discipline support upside potential, though valuation multiples like a P/E of 23.27 may limit near-term gains. Key risks include biosimilar threats post-2031 and ongoing legal challenges. Institutional activity shows increased holdings, reflecting confidence in the company's strategic direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Albertsons Companies Inc
Albertsons is the second-largest traditional grocer in America, operating 2,276 stores under 24 banners in 34 states (as of the end of fiscal 2021). Around 75% of stores have pharmacies, while nearly 20% also sell fuel. Albertsons has a significant private-label operation, accounting for around 20% of sales (excluding fuel). While its own brand assortment is mainly manufactured by third parties, Albertsons operates 20 food production plants (as of the end of fiscal 2021). Albertsons is a top-two grocer in two thirds of its major markets (as of early 2022, according to company data), and virtually all of its sales come from the United States.
Read more on ACI →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
